Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Weekly Wrap 5 August

Sophia Mavridis
August 5, 2022

Morning Bell 4 August

Paulina Peters
August 4, 2022

Morning Bell 3 August

Sophia Mavridis
August 3, 2022

Morning Bell 2 August

Paulina Peters
August 2, 2022

Morning Bell 1 August

Sophia Mavridis
August 1, 2022

Weekly Wrap 29 July

Sophia Mavridis
July 29, 2022

Morning Bell 28 July

Paulina Peters
July 28, 2022

Morning Bell 27 July

Paulina Peters
July 27, 2022

Morning Bell 26 July

Sophia Mavridis
July 26, 2022

Morning Bell 25 July

Sophia Mavridis
July 25, 2022

Weekly Wrap 22 July

Sophia Mavridis
July 22, 2022

Morning Bell 21 July

Paulina Peters
July 21, 2022